AlgiPharma AS

AlgiPharma, a biopharmaceutical company based in Norway, was founded in 2006 with a slogan of "A biopharmaceutical company with a focus on developing its first drug candidate for patients with Cystic Fibrosis." The company specializes in developing its proprietary alginate technology for drug delivery in various forms such as nanoparticles, small and large molecule based drugs, drug conjugates, and standalone API for diseases including cystic fibrosis, COPD, and infectious diseases. With expertise in addressing unmet medical needs, AlgiPharma boasts pharmaceutical scale production capabilities, protected by a broad family of patents. AlgiPharma's innovative alginate technology targets diseases characterized by abnormal mucus accumulation, non-invasive drug delivery challenges, microbial infection, biofilm formation, and antibiotic resistance. Despite no recent investment or disclosed investors, the company's focus on addressing critical medical needs through cutting-edge technology positions it as an attractive opportunity for potential venture capital allocation. This aligns with the industry's heightened interest in biotechnology and pharmaceuticals, making AlgiPharma a potential contender for attracting investment in the future.